Published on August 19, 2009 at 4:06 AM
GENova Biotherapeutics, Inc. (OTCBB: GVBP.OB), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Aaron Whiteman as its Chief Executive Officer.
Mr. Whiteman, is a graduate of Oxford University and London School of Economics. He will provide GENova with his unique blend of exceptional sales, marketing, business and networking skills, combined with solid business management experience and the vision to marry novel products with new market opportunities. Mr. Whiteman has extensive experience in team building and negotiation. He has previously worked with companies such as Pfizer (NYSE: PFE), Amgen (Nasdaq: AMGN), Myriad Genetics (Nasdaq: MYGN), Medarex (Nasdaq: MEDX), and Biogen Idec (Nasdaq: BIIB).
Mr. Whiteman said, "I am excited to provide the executive leadership to take GENova to its next stage of growth in this crucial phase of commercializing GENova's technology in the marketplace."
www.genovabio.com